Viewing Study NCT04444232


Ignite Creation Date: 2025-12-24 @ 9:47 PM
Ignite Modification Date: 2025-12-25 @ 7:26 PM
Study NCT ID: NCT04444232
Status: COMPLETED
Last Update Posted: 2020-06-23
First Post: 2020-06-19
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Cancer Communication Within Hispanic Social Networks
Sponsor: Fred Hutchinson Cancer Center
Organization:

Study Overview

Official Title: Cancer Communication Within Social Networks
Status: COMPLETED
Status Verified Date: 2020-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This trial examines cancer communication within Hispanic social networks. Hispanics have the lowest colorectal cancer screening rate of any major ethnic group and health interventions are crucially needed among Hispanics. Patient decision aids are health communication interventions designed to provide patients with targeted health information and have shown to improve colorectal cancer screening rates among Hispanics. The goal of this study is to investigate, in a sample of Hispanics, how a colorectal cancer decision aid aimed at increasing individuals' colorectal cancer screening behavior has effects on their alters' intention to get screened for colorectal cancer.
Detailed Description: OUTLINE:

Participants view an educational video on cancer and cancer screening options over 12 minutes. Participants also complete a phone survey over 10-15 minutes before attending the video session and 2 months after the video session.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
P30CA015704 NIH None https://reporter.nih.gov/quic… View
NCI-2020-04236 REGISTRY CTRP (Clinical Trial Reporting Program) View
8182 OTHER Fred Hutch/University of Washington Cancer Consortium View